Literature DB >> 20043788

Evaluation of a behavioral method for objective vision testing and identification of achromatopsia in dogs.

Monique M Garcia1, Gui-shuang Ying, Christina A Cocores, Jacqueline C Tanaka, András M Komáromy.   

Abstract

OBJECTIVE: To develop a quantifiable behavioral test for identification of achromatopsic dogs based on visual performance. ANIMALS: 14 dogs. PROCEDURES: A 3.6-m-long obstacle-avoidance course with 6 obstacle panels was developed from a preliminary 2.4-m-long course. Achromatopsic and visually normal control dogs were run through the course at 4 ambient light intensities (from dim to bright: 0.2, 25, 65, and 646 lux). Completion of 4 runs ranging from dimmest to brightest light intensity constituted 1 complete trial. Each dog underwent 3 trials. Transit times were measured and compared between dog groups and between light intensities by use of a generalized linear model and ANOVA.
RESULTS: At the 3 highest light intensities, the achromatopsic dogs needed significantly more time to pass through the obstacle course than the control animals. Compared with the mean transit time at the lowest light intensity, mean transit times were 2.6 times as long at 25 lux, 3.2 times as long at 65 lux, and 5.7 times as long at 646 lux. The achromatopsic dogs had signs of increasing difficulty navigating around the obstacle panels with increasing light intensities; this was not the situation for the control dogs. CONCLUSIONS AND CLINICAL RELEVANCE: A 3.6-m-long obstacle-avoidance course with 6 movable obstacle panels allowed identification of achromatopsic dogs at ambient light intensities >or= 25 lux based on transit times. This test could be helpful in the evaluation of new cone photoreceptor specific treatments.

Entities:  

Mesh:

Year:  2010        PMID: 20043788      PMCID: PMC2814178          DOI: 10.2460/ajvr.71.1.97

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  26 in total

1.  Gene therapy restores vision in a canine model of childhood blindness.

Authors:  G M Acland; G D Aguirre; J Ray; Q Zhang; T S Aleman; A V Cideciyan; S E Pearce-Kelling; V Anand; Y Zeng; A M Maguire; S G Jacobson; W W Hauswirth; J Bennett
Journal:  Nat Genet       Date:  2001-05       Impact factor: 38.330

2.  Functional MRI as a tool to assess vision in dogs: the optimal anesthetic.

Authors:  C K Willis; R P Quinn; W M McDonell; J Gati; J Parent; D Nicolle
Journal:  Vet Ophthalmol       Date:  2001-12       Impact factor: 1.644

3.  Hemeralopia in Alaskan Malamute pups.

Authors:  L F Rubin
Journal:  J Am Vet Med Assoc       Date:  1971-05-15       Impact factor: 1.936

4.  Clinical features of hemeralopia in the adult Alaskan malamute.

Authors:  L F Rubin
Journal:  J Am Vet Med Assoc       Date:  1971-05-15       Impact factor: 1.936

5.  Brightness discrimination in the dog.

Authors:  Gabriele Pretterer; Hermann Bubna-Littitz; Gerhard Windischbauer; Cornelia Gabler; Ulrike Griebel
Journal:  J Vis       Date:  2004-04-06       Impact factor: 2.240

6.  Canine CNGB3 mutations establish cone degeneration as orthologous to the human achromatopsia locus ACHM3.

Authors:  Duska J Sidjanin; Jennifer K Lowe; John L McElwee; Bruce S Milne; Taryn M Phippen; David R Sargan; Gustavo D Aguirre; Gregory M Acland; Elaine A Ostrander
Journal:  Hum Mol Genet       Date:  2002-08-01       Impact factor: 6.150

Review 7.  Cyclic nucleotide-gated ion channels.

Authors:  Kimberly Matulef; William N Zagotta
Journal:  Annu Rev Cell Dev Biol       Date:  2003       Impact factor: 13.827

8.  Day-blindness in three dogs: clinical and electroretinographic findings.

Authors:  Simon D Hurn; Chloë Hardman; Robin G Stanley
Journal:  Vet Ophthalmol       Date:  2003-06       Impact factor: 1.644

9.  In vivo gene therapy in young and adult RPE65-/- dogs produces long-term visual improvement.

Authors:  K Narfström; M L Katz; M Ford; T M Redmond; E Rakoczy; R Bragadóttir
Journal:  J Hered       Date:  2003 Jan-Feb       Impact factor: 2.645

10.  Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial.

Authors:  William W Hauswirth; Tomas S Aleman; Shalesh Kaushal; Artur V Cideciyan; Sharon B Schwartz; Lili Wang; Thomas J Conlon; Sanford L Boye; Terence R Flotte; Barry J Byrne; Samuel G Jacobson
Journal:  Hum Gene Ther       Date:  2008-10       Impact factor: 5.695

View more
  15 in total

1.  Exclusion of RPGRIP1 ins44 from primary causal association with early-onset cone-rod dystrophy in dogs.

Authors:  Tatyana Kuznetsova; Simone Iwabe; Kathleen Boesze-Battaglia; Sue Pearce-Kelling; Yim Chang-Min; Kendra McDaid; Keiko Miyadera; Andras Komaromy; Gustavo D Aguirre
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-08-15       Impact factor: 4.799

2.  Assessment of visual function and retinal structure following acute light exposure in the light sensitive T4R rhodopsin mutant dog.

Authors:  Simone Iwabe; Gui-Shuang Ying; Gustavo D Aguirre; William A Beltran
Journal:  Exp Eye Res       Date:  2016-04-13       Impact factor: 3.467

3.  Successful arrest of photoreceptor and vision loss expands the therapeutic window of retinal gene therapy to later stages of disease.

Authors:  William A Beltran; Artur V Cideciyan; Simone Iwabe; Malgorzata Swider; Mychajlo S Kosyk; Kendra McDaid; Inna Martynyuk; Gui-Shuang Ying; James Shaffer; Wen-Tao Deng; Sanford L Boye; Alfred S Lewin; William W Hauswirth; Samuel G Jacobson; Gustavo D Aguirre
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-12       Impact factor: 11.205

4.  Comparison of outcomes in cataractous eyes of dogs undergoing phacoemulsification versus eyes not undergoing surgery.

Authors:  Harathi Krishnan; Scott Hetzel; Gillian J McLellan; Ellison Bentley
Journal:  Vet Ophthalmol       Date:  2019-11-20       Impact factor: 1.644

5.  Gene therapy rescues cone function in congenital achromatopsia.

Authors:  András M Komáromy; John J Alexander; Jessica S Rowlan; Monique M Garcia; Vince A Chiodo; Asli Kaya; Jacqueline C Tanaka; Gregory M Acland; William W Hauswirth; Gustavo D Aguirre
Journal:  Hum Mol Genet       Date:  2010-04-08       Impact factor: 6.150

Review 6.  Dog models for blinding inherited retinal dystrophies.

Authors:  Simon M Petersen-Jones; András M Komáromy
Journal:  Hum Gene Ther Clin Dev       Date:  2015-02-11       Impact factor: 5.032

7.  Optimization of Retinal Gene Therapy for X-Linked Retinitis Pigmentosa Due to RPGR Mutations.

Authors:  William A Beltran; Artur V Cideciyan; Shannon E Boye; Guo-Jie Ye; Simone Iwabe; Valerie L Dufour; Luis Felipe Marinho; Malgorzata Swider; Mychajlo S Kosyk; Jin Sha; Sanford L Boye; James J Peterson; C Douglas Witherspoon; John J Alexander; Gui-Shuang Ying; Mark S Shearman; Jeffrey D Chulay; William W Hauswirth; Paul D Gamlin; Samuel G Jacobson; Gustavo D Aguirre
Journal:  Mol Ther       Date:  2017-05-27       Impact factor: 11.454

8.  Gene therapy reforms photoreceptor structure and restores vision in NPHP5-associated Leber congenital amaurosis.

Authors:  Gustavo D Aguirre; Artur V Cideciyan; Valérie L Dufour; Ana Ripolles-García; Raghavi Sudharsan; Malgorzata Swider; Roman Nikonov; Simone Iwabe; Sanford L Boye; William W Hauswirth; Samuel G Jacobson; William A Beltran
Journal:  Mol Ther       Date:  2021-03-27       Impact factor: 12.910

9.  Genomic deletion of CNGB3 is identical by descent in multiple canine breeds and causes achromatopsia.

Authors:  Connie Y Yeh; Orly Goldstein; Anna V Kukekova; Debbie Holley; Amy M Knollinger; Heather J Huson; Susan E Pearce-Kelling; Gregory M Acland; András M Komáromy
Journal:  BMC Genet       Date:  2013-04-20       Impact factor: 2.797

10.  A cyclic nucleotide-gated channel mutation associated with canine daylight blindness provides insight into a role for the S2 segment tri-Asp motif in channel biogenesis.

Authors:  Naoto Tanaka; Lucie Delemotte; Michael L Klein; András M Komáromy; Jacqueline C Tanaka
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.